Christian DepeursingeChristian Depeursinge is the leader of the Microvision and Micro-Diagnostics (MVD) group at the Advanced Photonics Laboratory of the Institute of Microengineering at EPFL (Ecole Polytechnique Fédérale de Lausanne), Switzerland (http://apl.epfl.ch/muvision). His research and expertise in biomedical engineering and optics is internationally acknowledged. His current research topics include coherent and incoherent Imaging applied to diagnostics in biology, His research group pioneered in the development of DHM technology. He worked on several projects developed in cooperation with European and international partners. He is author and co-author of over 100 papers published in peer reviewed journals, several book chapters and more than 30 patents. He has given more than 20 invited lectures and plenaries in the last five years. He developed many projects in cooperation with national and international industries. He is co-founder of a start-up company (Lyncée Tec SA: www.Lynceetec.com). He is currently teaching at EPFL and occasionally in foreign universities and institutes. Douglas HanahanDouglas Hanahan, born in Seattle, Washington, USA, received a bachelors degree in Physics from MIT (1976), and a Ph.D. in Biophysics from Harvard (1983). He worked at Cold Spring Harbor Laboratory in New York (1978-88) initially as a graduate student and then as a group leader. From 1988-2010 he was on the faculty of the Department of Biochemistry & Biophysics at UCSF in San Francisco. He has been elected to the American Academy of Arts & Sciences (2007), the Institute of Medicine (USA) (2008), the US National Academy of Science (2009), and EMBO (2010). In 2011, Hanahan received an honorary degree from the University of Dundee (UK).
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Freddy RadtkeFreddy Radtke obtained his Ph.D. in Molecular Biology from the University of Zürich in 1994. In 1995, he started his postdoctoral research in the laboratory of Michel Aguet at Genentech, Inc. (San Francisco, USA). In 1997, he returned to Switzerland with Michel Aguet and finished his postdoctoral fellowship at the Swiss Institute for Experimental Cancer Research (ISREC) in Lausanne. From 1999‑2005, he was a group leader and Associate Member at the Ludwig Institute for Cancer Research. Freddy Radtke then joined ISREC in January 2006 as a senior scientist and in July 2006, he was appointed Associate Professor at the EPFL School of Life Sciences
